Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways

Infection, Genetics and Evolution

Volumn 7, Issue 5, 2007, Pages 600-603

  Van Laethem, Kristel ^a,b   Pannecouque, Christophe ^a   Vandamme, Anne Mieke ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

HIV; Multinucleoside resistance; Mutations; Tenofovir

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; LAMIVUDINE; LOVIRIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN;

DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MOLECULAR STRUCTURE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34548313857     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2007.05.006     Document Type: Article

References (13)

1. Cherrington J.M., Mulato A.S., Fuller M.D., and Chen M.S. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob. Agents Chemother. 40 (1996) 2212-2216
2. Clark S.A., Calef C., and Mellors J.W. Mutations in retroviral genes associated with drug resistance. In: Leitner T., Foley B., Hahn B., Marx P., McCutchan F., Mellors J., Wolinsky S., and Korber B. (Eds). HIV Sequence Compendium 2005 (2005), Theoretical Biology and Biophysics Group, Los Alamos National Laboratory 80-174
3. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 40 (1997) 295-303
4. Gu Z., Salomon H., Cherrington J.M., Mulato A.S., Chen M.S., Yarchoan R., Foli A., Soqocio K.M., and Wainberg M.A. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 39 (1995) 1888-1891
5. Horwitz J.P., Chua J., and Noel M. Nucleoside V. The monomesylates of 1-(2′-deoxy-β-d-lyxofuranosyl)thymine. J. Org. Chem. 29 (1964) 2076-2078
6. Kagan R., Ross L., Winters M., Merigan T., Heseltine P., and Lewinski M. Adefovir-associated HIV-1 RT mutation K70E in the age of tenofovir. Antivir. Ther. 10 (2005) S103
7. Margot N.A., Isaacson E., McGowan I., Cheng A.K., Schooley R.T., and Miller M.D. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16 (2002) 1227-1235
8. Miller M.D., Margot N.A., Hertogs K., Larder B., and Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 20 (2001) 1025-1028
9. Miller M.D., Margot N., Lu B., Zhong L., Chen S.-S., Cheng A., and Wulfsohn M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 189 (2004) 837-846
10. Ross L., Gerondelis P., Liao Q., Wine B., Lim M., Shaefer M., Rodriguez A., Limoli K., Huang W., Parkin N.T., Gallant J., and Lanier R. Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naïve subjects treated with tenofovir/abacavir/lamivudine therapy. Antivir. Ther. 10 (2005) S102
11. Schmit J.-C., Cogniaux J., Hermans P., Van Vaeck C., Sprecher S., Van Remoortel B., Witvrouw M., Balzarini J., Desmyter J., De Clercq E., and Vandamme A.-M. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174 (1996) 962-968
12. Vandamme A.-M., Witvrouw M., Pannecouque C., Balzarini J., Van Laethem K., Schmit J.-C., Desmyter J., and De Clercq E. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In: Kinchington D., and Schinazi R.F. (Eds). Methods in Molecular Medicine: Antiviral Methods and Protocols (1999), The Humana Press
13. Wainberg M.A., Miller M.D., Quan Y., Salomon H., Mulato A.S., Lamy P.D., Margot N., Anton K.E., and Cherrington J.M. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. 4 (1999) 87-94